12mg Tesamorelin + 2mg Ipamorelin

Research Applications:

Dual Secretagogue Pathway Studies

This blend combines a GHRH analog framework with an ipamorelin-style ghrelin receptor agonist framework, allowing researchers to evaluate convergent growth-hormone secretagogue signaling from complementary receptor systems [1][2].
In controlled endocrine models, this pairing is useful for comparing GHRH receptor-driven pituitary stimulation with ghrelin receptor-mediated GH release while tracking downstream IGF-1 and feedback dynamics.

Pituitary Axis and Pulse-Release Models

The combination supports study designs focused on pulsatile GH output, receptor sensitivity, and hypothalamic-pituitary regulation. Researchers can use the model to compare secretagogue timing, dose-response curves, and downstream transcriptional outputs under standardized laboratory conditions.

Metabolic and Recovery Signaling

GH-axis signaling intersects with protein turnover, metabolic adaptation, and tissue-response pathways. This blend is therefore positioned for non-clinical studies of endocrine signaling rather than therapeutic use.

Referenced Citations:

1. Tesamorelin product content on Nuvora
   Source: Existing site content reused as a style and mechanism reference.
2. Ipamorelin product content on Nuvora
   Source: Existing site content reused as a style and mechanism reference.